Catalyst Brief

← Calendar

Readoutin 45d

Vertex Pharmaceuticals Incorporated — Suzetrigine

Phase 3 primary completion: Evaluation of the Long-term Safety and Effectiveness of Suzetrigine (SUZ) in Participants With Painful Diabetic Peripheral Neuropathy (DPN).

Date
Jan 2027
Type
Readout
Indication
Diabetic Peripheral Neuropathic Pain

Source ↗Add to calendar

Get told when this date moves

The weekly brief is free. Pro adds reminders 7 days and 1 day before.